We have shown that the combination of idelalisib and the novel Syk inhibitor, GS-9973, is effective at synergistically decreasing CLL cell viability, inhibiting BCR mediated signaling, and disrupting chemokine expression in CLL. This evidence concerns the gene SYK and B-cell chronic lymphocytic leukemia.